| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1056/NEJM199904293401706 |
| P698 | PubMed publication ID | 10219069 |
| P2093 | author name string | Sawyers CL | |
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| chronic myeloid leukemia | Q729735 | ||
| P1104 | number of pages | 11 | |
| P304 | page(s) | 1330-1340 | |
| P577 | publication date | 1999-04-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Chronic myeloid leukemia | |
| P478 | volume | 340 |
| Q39867512 | 3D QSAR models built on structure-based alignments of Abl tyrosine kinase inhibitors |
| Q40350288 | A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation |
| Q37097538 | A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets |
| Q39852216 | A Novel FRET-Based Biosensor for the Measurement of BCR-ABL Activity and Its Response to Drugs in Living Cells |
| Q36947496 | A Novel Four-Way Complex Variant Translocation Involving Chromosome 46,XY,t(4;9;19;22)(q25:q34;p13.3;q11.2) in a Chronic Myeloid Leukemia Patient |
| Q33384544 | A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. |
| Q89767923 | A Prognostic and Predictive Study of BCR-ABL Expression Based on Characterization of Fusion Transcripts |
| Q28387053 | A case of chronic myeloid leukemia in a diagnostic radiographer |
| Q42196145 | A case of chronic myeloid leukemia with features of essential thrombocythemia in peripheral blood and bone marrow |
| Q35821017 | A closer look at specific therapeutic strategies in leukemia |
| Q47136204 | A combined experimental and theoretical investigation on cellular blebbing |
| Q35849758 | A common phosphotyrosine signature for the Bcr-Abl kinase |
| Q34383220 | A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia. |
| Q37682689 | A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents |
| Q49013184 | A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits. |
| Q30008755 | A novel AHI-1-BCR-ABL-DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy |
| Q36611704 | A novel cytogenetic abnormality t(7;8)(p11.2:q11.2) and a four-way Philadelphia translocation in an imatinib mesylate-resistant chronic myeloid leukemia patient |
| Q40369957 | A novel t(3;12)(q21;p13) translocation in a patient with accelerated chronic myeloid leukemia after imatinib and nilotinib therapy |
| Q40386894 | A nuclear tyrosine phosphorylation circuit: c-Jun as an activator and substrate of c-Abl and JNK. |
| Q53336336 | A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. |
| Q33402939 | A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia |
| Q41153525 | A rare case of a three way complex variant positive Philadelphia translocation involving chromosome (9;11;22)(q34;p15;q11) in chronic myeloid leukemia: A case report |
| Q28534337 | A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL |
| Q37976243 | AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications |
| Q84943840 | Aberrant microRNA expression and its implications in the pathogenesis of leukemias |
| Q30513412 | Abl regulates planar polarized junctional dynamics through β-catenin tyrosine phosphorylation |
| Q42804141 | Abl-1-bridged tyrosine phosphorylation of VASP by Abelson kinase impairs association of VASP to focal adhesions and regulates leukaemic cell adhesion |
| Q36387433 | Accelerated phase chronic myeloid leukemia: evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase |
| Q35774432 | Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib |
| Q37657488 | Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors |
| Q54336250 | Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. |
| Q35560205 | Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes |
| Q46742939 | Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis |
| Q47868737 | Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia |
| Q42367100 | Alterations in the Reactive Oxygen Species in Peripheral Blood of Chronic Myeloid Leukaemia Patients from Northern India |
| Q52609598 | Altered expression of circadian clock genes in human chronic myeloid leukemia. |
| Q47420917 | Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells. |
| Q35903505 | Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia |
| Q36623903 | Alternative splicing of apoptosis-related genes in imatinib-treated K562 cells identified by exon array analysis |
| Q73467024 | Amplification of the BCR/ABL fusion gene clustered on a masked Philadelphia chromosome in a patient with myeloblastic crisis of chronic myelocytic leukemia |
| Q26782165 | An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians |
| Q37334825 | An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. |
| Q43235803 | An overview of the role of platelets in angiogenesis, apoptosis and autophagy in chronic myeloid leukaemia. |
| Q34134516 | Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. |
| Q38723954 | Anti-Proliferative Effects of Dendrophthoe pentandra Methanol Extract on BCR/ABL-Positive and Imatinib-Resistant Leukemia Cell Lines |
| Q36480592 | Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors |
| Q36466443 | Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm |
| Q28361750 | Are occupational, hobby, or lifestyle exposures associated with Philadelphia chromosome positive chronic myeloid leukaemia? |
| Q34569056 | Assessment of interleukin 1β serum level in different responder groups and stages of chronic myeloid leukemia patients on imatinb mesylate therapy |
| Q28215538 | Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway |
| Q53724655 | Association of GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms with clinical response to imatinib mesylate treatment among Malaysian chronic myeloid leukaemia patients. |
| Q33359521 | Autoimmune thrombocytopenia in chronic myeloid leukemia treated with interferon-alpha: differential diagnosis and possible pathogenesis |
| Q33345338 | Autologous stem cell transplantation for patients with chronic myeloid leukemia. The Argentine Group of Bone Marrow Transplantation (GATMO) experience |
| Q45712588 | BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study |
| Q38293633 | BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. |
| Q39656321 | BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients |
| Q44040285 | BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl |
| Q40666171 | BCR/ABL activates mdm2 mRNA translation via the La antigen |
| Q40771883 | BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance |
| Q36375641 | BIRC6 mediates imatinib resistance independently of Mcl-1. |
| Q35579046 | Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia |
| Q99555829 | Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to |
| Q40827710 | Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells |
| Q34366423 | Bcr-Abl inhibition as a modality of CML therapeutics |
| Q28215884 | Bcr-Abl is a "molecular switch" for the decision for growth and differentiation in hematopoietic stem cells |
| Q34145565 | Bcr-Abl variants: biological and clinical aspects |
| Q30175351 | Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy |
| Q36884361 | Best Practices in Chronic Myeloid Leukemia Monitoring and Management |
| Q37729105 | Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells. |
| Q52367394 | Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. |
| Q38183422 | Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia |
| Q38184553 | Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview |
| Q39257678 | Bosutinib treatment for Philadelphia chromosome-positive leukemias |
| Q38135813 | Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia |
| Q54349085 | Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. |
| Q34350639 | Bulge-like asymmetric heterodye clustering in DNA duplex results in efficient quenching of background emission based on the maximized excitonic interaction |
| Q61796550 | C/EBPβ is a critical mediator of IFN-α-induced exhaustion of chronic myeloid leukemia stem cells |
| Q35864103 | C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion. |
| Q54471021 | CBL-B is required for leukemogenesis mediated by BCR-ABL through negative regulation of bone marrow homing. |
| Q91812839 | CRISPR/CAS9-mediated knockout of Abi1 inhibits p185Bcr-Abl-induced leukemogenesis and signal transduction to ERK and PI3K/Akt pathways |
| Q37598464 | Cancer driver-passenger distinction via sporadic human and dog cancer comparison: a proof-of-principle study with colorectal cancer. |
| Q89081284 | Cancer-mutation network and the number and specificity of driver mutations |
| Q37409768 | Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells |
| Q43734636 | Cells from chronic myelogenous leukaemia patients at presentation exhibit multidrug resistance not mediated by either MDR1 or MRP1. |
| Q48264455 | Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report |
| Q40636311 | Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro |
| Q40427115 | Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability |
| Q33580572 | Changing therapy from Glivecto a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports |
| Q37977471 | Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications |
| Q34342905 | Chemistry-based functional proteomics for drug target deconvolution |
| Q37607094 | Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. |
| Q37025973 | Chronic Myeloid Leukemia in Nigerian Patients: Anemia is an Independent Predictor of Overall Survival |
| Q58326895 | Chronic Myeloid Leukemia with Increased Granulocyte Progenitors in Mice Lacking JunB Expression in the Myeloid Lineage |
| Q34268535 | Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment |
| Q34135279 | Chronic myelogenous leukaemia |
| Q34308917 | Chronic myelogenous leukaemia--new therapeutic principles. |
| Q35166848 | Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies |
| Q34364223 | Chronic myelogenous leukemia: laboratory diagnosis and monitoring |
| Q34210064 | Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma |
| Q79169252 | Chronic myeloid leukemia |
| Q43061582 | Chronic myeloid leukemia and allogeneic natural killer cells: a surprising dialogue |
| Q43765290 | Chronic myeloid leukemia and tyrosine kinase inhibitors |
| Q58567334 | Chronic myeloid leukemia extramedullary blast crisis presenting as central nervous system leukemia: A case report |
| Q37023335 | Chronic myeloid leukemia in 2007. |
| Q34481214 | Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors--the first molecular targeted treatment |
| Q46868276 | Chronic myeloid leukemia. Introduction |
| Q35291843 | Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts |
| Q49888044 | Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. |
| Q35750850 | Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis |
| Q38817367 | Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib |
| Q73924642 | Clinical significance of reverse BCR/ABL gene rearrangement in Ph-negative chronic myelogenous leukemia |
| Q35667438 | Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy |
| Q50884247 | Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy. |
| Q92618149 | Co-existence of t(9;22) and t(8;21) in primary blast phase of chronic myelogenous leukemia: clinical experience and literature review |
| Q33766467 | Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity |
| Q40668019 | Comparison of Dasatinib, Nilotinib, and Imatinib in the Treatment of Chronic Myeloid Leukemia |
| Q80810338 | Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias |
| Q37424789 | Complex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid Leukemia. |
| Q24631412 | Complex landscapes of somatic rearrangement in human breast cancer genomes |
| Q54344826 | Complex/variant translocations in chronic myelogenous leukemia (CML): genesis and prognosis with 4 new cases. |
| Q36682691 | Computational prediction of cancer-gene function |
| Q28469309 | Conservation, variability and the modeling of active protein kinases |
| Q44488212 | Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. |
| Q41971118 | Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression |
| Q36490622 | Conventional cytogenetics and FISH in the detection of BCR/ABL fusion in chronic myeloid leukemia (CML). |
| Q28214984 | Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia |
| Q24241965 | Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation |
| Q46492416 | Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia |
| Q45113883 | Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia |
| Q46447882 | Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach |
| Q36648249 | Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. |
| Q30167857 | Crk family adaptors-signalling complex formation and biological roles |
| Q27667290 | Crystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide Class |
| Q24644654 | Cytogenetic features in myelodysplastic syndromes |
| Q47291002 | Cytogenetic testing for therapeutic indication in cancer |
| Q35050409 | Cytokine signalling and disease |
| Q35143436 | Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor |
| Q36694195 | Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ. |
| Q40007199 | DC generation from peripheral blood mononuclear cells in patients with chronic myeloid leukemia: Influence of interferons on DC yield and functional properties |
| Q79139530 | Dasatinib |
| Q36462473 | Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia |
| Q37254728 | Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia |
| Q38044753 | Dasatinib for the treatment of Philadelphia chromosome-positive leukemias |
| Q39739850 | Dasatinib for the treatment of chronic myeloid leukemia |
| Q37523302 | Dasatinib in chronic myeloid leukemia: a review. |
| Q37385960 | Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations |
| Q37711769 | Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia. |
| Q58777160 | Deciphering Key Pharmacological Pathways of Qingdai Acting on Chronic Myeloid Leukemia Using a Network Pharmacology-Based Strategy |
| Q34483093 | Decoding the fine-scale structure of a breast cancer genome and transcriptome |
| Q54485229 | Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon. |
| Q74082581 | Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma |
| Q74166937 | Deletion of sequences flanking the t(9;22) breakpoint: a secondary genetic event associated with loss of cytogenetic response to interferon in a Philadelphia-positive chronic myeloid leukaemia patient |
| Q40801872 | Deletion of the Src homology 3 domain and C-terminal proline-rich sequences in Bcr-Abl prevents Abl interactor 2 degradation and spontaneous cell migration and impairs leukemogenesis |
| Q41472526 | Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells |
| Q55025859 | Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia. |
| Q34082540 | Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML) |
| Q37698231 | Detection of BCR-ABL Positive Cells in an Asymptomatic Patient: A Case Report and Literature Review |
| Q36075657 | Determinants of Overall and Progression-Free Survival of Nigerian Patients with Philadelphia-Positive Chronic Myeloid Leukemia |
| Q36677315 | Development and dynamics of robust T-cell responses to CML under imatinib treatment |
| Q38819928 | Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase |
| Q38088317 | Development of novel benzotriazines for drug discovery |
| Q35164392 | Diagnosis, treatment, and nursing care of patients with chronic leukemia |
| Q49993294 | Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update. |
| Q36933601 | Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study |
| Q40039722 | Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs |
| Q64085667 | Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha |
| Q34710642 | Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics |
| Q54267213 | Discovery of novel Bcr-Abl inhibitors with diacylated piperazine as the flexible linker. |
| Q37010048 | Disruption of Survivin in K562 cells elevates telomerase activity and protects cells against apoptosis induced by the Bcr-abl kinase inhibitor STI571. |
| Q34980358 | Dissecting the molecular mechanism of chronic myelogenous leukemia using murine models |
| Q62057736 | Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia |
| Q24810666 | Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region |
| Q34056631 | Drosophila Abelson kinase mediates cell invasion and proliferation through two distinct MAPK pathways |
| Q46123265 | Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders |
| Q35337927 | Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. |
| Q93048204 | Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy |
| Q39134217 | Dynamic transcriptomes of human myeloid leukemia cells |
| Q33345245 | Dynamics and potential impact of the immune response to chronic myelogenous leukemia |
| Q44605531 | Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. |
| Q40464802 | Dysregulated expression of the major telomerase components in leukaemic stem cells. |
| Q44117833 | Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha |
| Q34396079 | Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial |
| Q28469312 | Effect of cellular quiescence on the success of targeted CML therapy |
| Q33866597 | Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate |
| Q80559670 | Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha |
| Q34480473 | Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy. |
| Q40539487 | Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia |
| Q37150014 | Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia |
| Q39084910 | Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation |
| Q38928611 | Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition |
| Q47592900 | Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI. |
| Q35377397 | Epigenetic regulation of cathepsin L expression in chronic myeloid leukaemia |
| Q30873646 | Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib |
| Q46886119 | Erythroid variant of chronic myelogenous leukemia |
| Q44719689 | Establishment and phenotypic characterization of human U937 cells with inducible P210 BCR/ABL expression reveals upregulation of CEACAM1 (CD66a). |
| Q39909602 | Estimation of the prevalence and direct medical costs of chronic myeloid leukemia in the I.R. of Iran in the era of tyrosine kinase inhibitors |
| Q35051720 | European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients |
| Q33412429 | Evaluation of the safety of imatinib mesylate in 200 iraqi patients with chronic myeloid leukemia in the chronic phase: single-center study |
| Q40100583 | Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing |
| Q38306649 | Expression of CCL9/MIP-1gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells |
| Q40114134 | Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells |
| Q53561107 | Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase. |
| Q44598656 | FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib |
| Q50337087 | FMNL1 promotes proliferation and migration of leukemia cells. |
| Q37842585 | FMS-like tyrosine kinase 3 inhibitors: a patent review |
| Q34747208 | Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia |
| Q73668254 | Flow cytometric analysis of aneuploidy and S-phase fraction in chronic myeloid leukemia patients: role in early detection of accelerated phase |
| Q36334327 | FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis |
| Q43847051 | Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells |
| Q43825958 | Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. |
| Q53197147 | Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models. |
| Q39196420 | Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia |
| Q34921317 | Gastrointestinal stromal tumors: rationale for surgical adjuvant trials with imatinib |
| Q41682548 | Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia. |
| Q53347361 | Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. |
| Q53366009 | Genetic polymorphism of CYP3A5 in Indian chronic myeloid leukemia patients. |
| Q57240022 | Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis |
| Q40345134 | Geographic and income variations in age at diagnosis and incidence of chronic myeloid leukemia |
| Q47136924 | Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib. |
| Q39742346 | Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment |
| Q28473957 | Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate |
| Q51806460 | HLA risk markers for chronic myelogenous leukemia in Eastern Canada. |
| Q38033115 | Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis |
| Q41203712 | Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia. |
| Q33398485 | Hematologic toxicities of small molecule tyrosine kinase inhibitors |
| Q38140001 | Hematological malignancies: role of miRNAs and their in silico aspects |
| Q36987654 | Hematopoietic and Leukemic Stem Cells Have Distinct Dependence on Tcf1 and Lef1 Transcription Factors. |
| Q79801204 | Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations |
| Q52074948 | Hematopoietic stem-cell transplantation from an unrelated donor. |
| Q36618587 | Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells |
| Q39702824 | High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia |
| Q35104353 | High affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronic myelogenous leukaemia |
| Q35114876 | High frequency of fusion transcripts involving TCF7L2 in colorectal cancer: novel fusion partner and splice variants |
| Q40646024 | High-resolution analysis of acquired genomic imbalances in bone marrow samples from chronic myeloid leukemia patients by use of multiple short DNA probes |
| Q79849689 | High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations |
| Q35557122 | Histiocytic lesions involving the bone marrow |
| Q28540799 | Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias |
| Q43788363 | Imatinib |
| Q34022596 | Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia |
| Q35045474 | Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy |
| Q35870613 | Imatinib as a paradigm of targeted therapies |
| Q46474195 | Imatinib in pregnancy. |
| Q44351275 | Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis |
| Q44319713 | Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias |
| Q33844109 | Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy |
| Q37183434 | Imatinib mesylate for the treatment of chronic myeloid leukemia |
| Q35828742 | Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukemia |
| Q35143966 | Imatinib mesylate in the treatment of chronic myeloid leukaemia |
| Q46693880 | Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia |
| Q34975667 | Imatinib mesylate, the first molecularly targeted gene suppressor |
| Q54557849 | Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients. |
| Q36751212 | Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib |
| Q51040414 | Immunological effects of interferon-alpha on chronic myelogenous leukemia. |
| Q34046541 | Immunological off-target effects of imatinib |
| Q44955106 | Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts |
| Q24816866 | Impaired DNA replication within progenitor cell pools promotes leukemogenesis. |
| Q57063931 | Implication and Regulation of AMPK during Physiological and Pathological Myeloid Differentiation |
| Q43722517 | Implications of signal transduction inhibition for the treatment of chronic myeloid leukemia |
| Q42409714 | Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance. |
| Q51066255 | In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia. |
| Q35812209 | In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study |
| Q42087264 | Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells |
| Q46577685 | Induction of centrosome and chromosome aberrations by imatinib in vitro |
| Q54216113 | Influence of CYP1A1, GST polymorphisms and susceptibility risk of chronic myeloid leukemia in Syrian population. |
| Q97524510 | Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib |
| Q44051856 | Infusion of peripheral blood stem cells collected at diagnosis, with maintenance of the treatment, resulted in Ph-negative recovery in a chronic myeloid leukaemia patient in persisting aplasia on STI-571 therapy |
| Q36071481 | Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease |
| Q35900937 | Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. |
| Q37487526 | Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. |
| Q36597361 | Interferon gamma modulates sensitivity of CML cells to tyrosine kinase inhibitors |
| Q35058690 | Interferon-alfa for chronic myeloid leukemia |
| Q53963577 | Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. |
| Q44248573 | Interferons and hematology |
| Q43084694 | Interferons in hematopoiesis and leukemia |
| Q40708026 | Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors |
| Q54787150 | Intracellular cytokine analysis of interferon-gamma in T cells of patients with chronic myeloid leukemia. |
| Q38432973 | Investigating critical genes and gene interaction networks that mediate cyclophosphamide sensitivity in chronic myelogenous leukemia |
| Q30167883 | Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation |
| Q35097392 | Is there a cloud in the silver lining for imatinib? |
| Q38216654 | JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis |
| Q42149644 | Karyotypic findings in chronic myeloid leukemia cases undergoing treatment |
| Q37472874 | Kinase drug discovery approaches in chronic myeloproliferative disorders |
| Q35909275 | Kinase inhibitors in leukemia |
| Q35814037 | Kinase inhibitors in the treatment of immune-mediated disease |
| Q36735557 | Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival |
| Q44440140 | Kinetics of hematopoiesis in bone marrow cultures from patients with chronic myeloid leukemia: effect of recombinant cytokines in dexter-type long-term cultures |
| Q39172206 | L-amino acid oxidase isolated from Bothrops pirajai induces apoptosis in BCR-ABL-positive cells and potentiates imatinib mesylate effect |
| Q36672128 | Leukemic stem cells: where do they come from? |
| Q34207897 | Life and death in the JUNgle. |
| Q37360438 | Lifestyle and dietary factors in relation to risk of chronic myeloid leukemia in the NIH-AARP Diet and Health Study |
| Q45231820 | Long-term follow-up of patients with chronic myeloid leukemia having received autologous stem cell transplantation |
| Q35595870 | Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors |
| Q45113880 | Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia |
| Q36508955 | Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis |
| Q44703351 | Lower than expected cytogenetic and molecular response to imatinib in Mexican patients with chronic myelogenous leukemia |
| Q35409292 | Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction |
| Q35804449 | MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825 |
| Q37322180 | MIP-1α/CCL3-mediated maintenance of leukemia-initiating cells in the initiation process of chronic myeloid leukemia |
| Q35203394 | Management of molecular-targeted therapy for chronic myelogenous leukemia |
| Q36619319 | Mathematical models of targeted cancer therapy |
| Q24532168 | Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions |
| Q37618888 | Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. |
| Q37896015 | Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia |
| Q40081650 | Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells |
| Q46113055 | Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras. |
| Q35103557 | MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors |
| Q38215614 | MicroRNAs in the pathogenesis of myelodysplastic syndromes and myeloid leukaemia |
| Q36666798 | Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling |
| Q92473999 | Microfluidic device for expedited tumor growth towards drug evaluation |
| Q33394812 | Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib |
| Q38218300 | Model-based cost-effectiveness analyses for the treatment of chronic myeloid leukaemia: a review and summary of challenges |
| Q38361603 | Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy |
| Q46534692 | Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan. |
| Q54343040 | Molecular beacon-based fluorescence biosensor for the detection of gene fragment and PCR amplification products related to chronic myelogenous leukemia. |
| Q35790781 | Molecular biological design of novel antineoplastic therapies |
| Q34246740 | Molecular biology of chronic myeloid leukemia |
| Q33750753 | Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission |
| Q43082879 | Molecular monitoring in patients with chronic myelogenous leukemia |
| Q44582792 | Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission |
| Q37979587 | Molecular resistance: an early indicator for treatment change? |
| Q50053531 | Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia. |
| Q34349062 | Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors |
| Q36654030 | Monitoring your patients with chronic myeloid leukemia |
| Q35062458 | Mouse cancer models as a platform for performing preclinical therapeutic trials |
| Q34205443 | Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. |
| Q29615030 | Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia |
| Q36791537 | Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond. |
| Q34734850 | Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model |
| Q35557105 | Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases |
| Q39459749 | N-[2-Methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine as a scaffold for the synthesis of inhibitors of Bcr-Abl. |
| Q34522789 | NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia |
| Q38281185 | NF-κB suppresses ROS levels in BCR-ABL(+) cells to prevent activation of JNK and cell death |
| Q30009530 | NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors |
| Q37574957 | NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor. |
| Q33383407 | New dosing schedules of dasatinib for CML and adverse event management |
| Q45951595 | New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. |
| Q33378852 | Nilotinib |
| Q34639998 | Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. |
| Q33398183 | Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results |
| Q41899882 | Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results |
| Q37403226 | Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. |
| Q35904180 | Non-steady-state hematopoiesis regulated by the C/EBPβ transcription factor |
| Q34542144 | Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? |
| Q93018937 | Novel analytical methods to interpret large sequencing data from small sample sizes |
| Q27824789 | Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571. |
| Q57192334 | Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies |
| Q38725483 | Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia |
| Q37295261 | Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy |
| Q34926078 | Only three driver gene mutations are required for the development of lung and colorectal cancers |
| Q89543368 | Optimization of combination therapy for chronic myeloid leukemia with dosing constraints |
| Q51733092 | Oral Effects and Early Implant Survival Results After Imatinib Discontinuation Therapy for Chronic Myelogenous Leukemia: A Case Report. |
| Q36853551 | Orientation and oligomerization specificity of the Bcr coiled-coil oligomerization domain |
| Q38666371 | Outcome of 3 pregnancies in a patient with chronic myeloid leukemia who received 3 types of tyrosine kinase inhibitors each in different pregnancy: follow-up of the case with a review of published reports |
| Q35596200 | Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure |
| Q38216677 | Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy |
| Q45936261 | Outpacing cancer. |
| Q38671390 | Overcoming multiple myeloma drug resistance in the era of cancer 'omics'. |
| Q37284030 | P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia |
| Q27671025 | P6981, An Arylstibonic Acid, Is a Novel Low Nanomolar Inhibitor of cAMP Response Element-Binding Protein Binding to DNA |
| Q92647093 | Paediatric chronic myeloid leukaemia: Is it really a different disease? |
| Q33765281 | Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor |
| Q35560189 | Pathology of the myeloproliferative diseases |
| Q35553345 | Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment |
| Q55066758 | Persistent major molecular response to nilotinib therapy in a patient with chronic myeloid leukemia harboring ABL gene T315I mutation. |
| Q37776547 | Personalized therapies in the cancer "omics" era |
| Q34710684 | Perspectives on the development of a molecularly targeted agent |
| Q35102183 | Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). |
| Q37464749 | Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia |
| Q43591848 | Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission |
| Q40709933 | Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. |
| Q49979433 | Phosphoproteomics-Based Profiling of Kinase Activities in Cancer Cells. |
| Q28207611 | Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene |
| Q35022522 | Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins |
| Q43207016 | Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes |
| Q39531163 | Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor |
| Q58572255 | Precursor B cell lymphoid blast crisis of chronic myeloid leukemia with novel chromosomal abnormalities: A case report |
| Q37921593 | Predictive biomarkers: a paradigm shift towards personalized cancer medicine |
| Q34263570 | Preparation and application of antibodies to phosphoamino acid sequences |
| Q44161665 | Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia. |
| Q37412144 | Prevalence of Abelson murine leukemia viral oncogene homolog-breakpoint cluster region fusions and correlation with peripheral blood parameters in chronic myelogenous leukemia patients in Lorestan Province, Iran |
| Q45991052 | Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. |
| Q36694985 | Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase |
| Q38095956 | Prognostic Significance of Treatment Response in CML in View of Current Recommendations for Treatment and Monitoring |
| Q42368110 | Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression. |
| Q58494049 | Protein chimerism: Novel source of protein diversity in humans adds complexity to bottom-up proteomics |
| Q37636455 | Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells |
| Q57790875 | Quantitative PCR identifies a minimal deleted region of 120 kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome |
| Q54626064 | Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells. |
| Q37190370 | RalA, a GTPase targeted by miR-181a, promotes transformation and progression by activating the Ras-related signaling pathway in chronic myelogenous leukemia. |
| Q61804715 | Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation |
| Q40776714 | Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette |
| Q34644820 | Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia |
| Q36318531 | Recent advances in targeted therapy of human myelogenous leukaemia |
| Q35524714 | Recent advances in the path toward the cure for chronic myeloid leukemia |
| Q36827373 | Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition |
| Q37115618 | Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate |
| Q34103653 | Regulation of cell death by the Abl tyrosine kinase |
| Q36927973 | Regulation of hematopoiesis and the hematopoietic stem cell niche by Wnt signaling pathways |
| Q40357233 | Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells |
| Q44851706 | Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia |
| Q34804758 | Resistance in the land of molecular cancer therapeutics |
| Q35128883 | Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back |
| Q44826305 | Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome |
| Q36757457 | Review: new biological insights in early clinical studies |
| Q37810111 | Role of gene-expression profiling in chronic myeloid leukemia |
| Q38866630 | Role of macrophage inflammatory protein (MIP)-1α/CCL3 in leukemogenesis. |
| Q73398054 | Role of pretransplant interferon-α(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers |
| Q45951572 | S-phase fraction as response marker in patients with chronic myeloid leukemia. |
| Q33941357 | STAT signaling in the pathogenesis and treatment of leukemias |
| Q34929139 | STI-571 in chronic myelogenous leukaemia |
| Q34583847 | STI571 (Gleevec) as a paradigm for cancer therapy |
| Q35193288 | STI571 as a targeted therapy for CML. |
| Q34571800 | STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia |
| Q44047912 | Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT). |
| Q38319925 | Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. |
| Q38743474 | Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro |
| Q44224219 | Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. |
| Q38430207 | Selective surface marker and miRNA profiles of CD34+ blast-derived microvesicles in chronic myelogenous leukemia |
| Q39588677 | Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. |
| Q34769838 | Signaling via the interferon-alpha receptor in chronic myelogenous leukemia cells |
| Q46344190 | Silencing of membrane-associated sialidase Neu3 diminishes apoptosis resistance and triggers megakaryocytic differentiation of chronic myeloid leukemic cells K562 through the increase of ganglioside GM3. |
| Q35548143 | Simultaneous determination of the novel tyrosine kinase inhibitor meditinib and its active metabolite demethylation meditinib in monkey plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies |
| Q37150507 | Sirtuins, tissue maintenance, and tumorigenesis |
| Q33559005 | Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation |
| Q35735401 | Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder |
| Q36605667 | Somatic stem cells and the origin of cancer |
| Q42827035 | Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells |
| Q33348507 | Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome |
| Q44338515 | Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia |
| Q36150854 | Src kinases as targets for B cell acute lymphoblastic leukaemia therapy |
| Q46931926 | Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal |
| Q35459748 | Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors |
| Q38219625 | Stem cell dynamics in homeostasis and cancer of the intestine |
| Q30984215 | Strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia. |
| Q37027402 | Strategies for overcoming imatinib resistance in chronic myeloid leukemia |
| Q35968384 | Strategies to overcome resistance to targeted protein kinase inhibitors |
| Q27678454 | Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain |
| Q55070175 | Studies of N(9)-arenthenyl purines as novel DFG-in and DFG-out dual Src/Abl inhibitors using 3D-QSAR, docking and molecular dynamics simulations. |
| Q33362624 | Subdural hematomas during CML therapy with imatinib mesylate. |
| Q33708377 | Successful Pregnancy and Delivery in a Patient with Chronic Myeloid Leukemia while on Dasatinib Therapy. |
| Q83288649 | Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa |
| Q44237026 | Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis |
| Q54616418 | Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene. |
| Q41649368 | Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase. |
| Q36749168 | Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells |
| Q46437707 | Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience |
| Q52546912 | Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. |
| Q53851086 | Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. |
| Q36300062 | Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics. |
| Q32118812 | Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells |
| Q92504202 | Systemic Pharmacological Approach to Identification and Experimental Verification of the Effect of Anisi Stellati Fructus Extract on Chronic Myeloid Leukemia Cells |
| Q90086553 | TARGETING LEUKEMIA STEM CELL RESISTANCE IN CHRONIC MYELOGENOUS LEUKEMIA |
| Q40795252 | TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3'-kinase/protein kinase B signaling pathway |
| Q43766077 | TFIIH functions are altered by the P210BCR-ABL oncoprotein produced on the Philadelphia chromosome |
| Q36356216 | TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia |
| Q80140951 | Targeted chronic myeloid leukemia therapy: Seeking a cure |
| Q35164384 | Targeted therapies for the treatment of leukemia |
| Q33915973 | Targeted treatment of chronic myeloid leukemia: role of imatinib. |
| Q41279430 | Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex |
| Q39206405 | Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ CML stem/progenitor cells |
| Q36697774 | Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex |
| Q37122686 | Targeting survival pathways in chronic myeloid leukaemia stem cells |
| Q36967858 | The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias |
| Q40786423 | The Dbl homology domain of BCR is not a simple spacer in P210BCR-ABL of the Philadelphia chromosome |
| Q41914260 | The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl |
| Q57491369 | The Ins and Outs of Autophagy and Metabolism in Hematopoietic and Leukemic Stem Cells: Food for Thought |
| Q33967112 | The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl |
| Q40399343 | The Runx1 transcription factor controls CSF-1-dependent and -independent growth and survival of macrophages |
| Q38375186 | The Semantics of Priapism and the First Sign of Chronic Myeloid Leukemia. |
| Q33610879 | The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts |
| Q35075559 | The age incidence of chronic myeloid leukemia can be explained by a one-mutation model |
| Q40165123 | The anticancer drug imatinib induces cellular autophagy. |
| Q55092219 | The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia. |
| Q39475895 | The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells |
| Q24300807 | The c-Fes tyrosine kinase cooperates with the breakpoint cluster region protein (Bcr) to induce neurite extension in a Rac- and Cdc42-dependent manner |
| Q35026699 | The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis. |
| Q36081983 | The development and application of imatinib |
| Q34837015 | The emergence of resistance to targeted cancer therapeutics |
| Q73274594 | The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy |
| Q40887253 | The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways. |
| Q37082725 | The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up |
| Q37448763 | The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib |
| Q34369606 | The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib |
| Q30167860 | The role of Gads in hematopoietic cell signalling. |
| Q91934176 | The role of phosphorylation of MLF2 at serine 24 in BCR-ABL leukemogenesis |
| Q53515689 | The story of chronic myeloid leukaemia. |
| Q27653890 | The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2) |
| Q35062049 | The treatment of pediatric chronic myelogenous leukemia in the imatinib era |
| Q36822880 | Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). |
| Q24658483 | Therapeutic targeting of Janus kinases |
| Q36794538 | Therapeutic targets in chronic myeloid leukaemia |
| Q46616933 | Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study |
| Q34996707 | Towards the small and the beautiful: a small dibromotyrosine derivative from Pseudoceratina sp. sponge exhibits potent apoptotic effect through targeting IKK/NFκB signaling pathway |
| Q43919055 | Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia |
| Q28138004 | Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck |
| Q38685696 | Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: a case report |
| Q38247744 | Translational hematology |
| Q38585916 | Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia. |
| Q35190480 | Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies. |
| Q35627994 | Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells |
| Q53204377 | Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country. |
| Q36540561 | Treatment of chronic myeloid leukemia with imatinib mesylate |
| Q33391185 | Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib |
| Q45026390 | Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysis |
| Q37431597 | Treatment selection after imatinib resistance in chronic myeloid leukemia |
| Q33926114 | Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. |
| Q33289385 | Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. |
| Q29617990 | Tumour heterogeneity and cancer cell plasticity |
| Q90047078 | Tyrosine Kinase Inhibition: a New Perspective in the Fight against HIV |
| Q34718214 | Tyrosine kinase fusion genes in chronic myeloproliferative diseases. |
| Q39226064 | Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection. |
| Q43613017 | Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution |
| Q37663655 | Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice |
| Q43159083 | Use of oncolytic viruses for the eradication of drug-resistant cancer cells |
| Q48263612 | Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. |
| Q89939868 | Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study |
| Q24318820 | Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution |
| Q38708854 | What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature |
| Q33903925 | White cells 2: impact of understanding the molecular basis of haematological malignant disorders on clinical practice |
| Q28078210 | Zebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights |
| Q46706721 | Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. |
| Q39646637 | c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis |
| Q24291294 | c-Abl tyrosine kinase binds and phosphorylates phospholipid scramblase 1 |
| Q36639038 | c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia |
| Q28582087 | cAbl tyrosine kinase mediates reactive oxygen species- and caveolin-dependent AT1 receptor signaling in vascular smooth muscle: role in vascular hypertrophy |
| Q34204486 | del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia |
| Q39674140 | hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis |
| Q42459181 | p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells |
Search more.